Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.

Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.

The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients…